Drug Details

General Information of the Drug (ID: DR1137)
Name
Meropenem
Synonyms
meropenem; 96036-03-2; Merrem; Meropenem anhydrous; Meropenemum; Antibiotic SM 7338; MERONEM; SM-7338; MEPM; 119478-56-7; UNII-YOP6PX0BAO; CHEBI:43968; Meropenemum [INN-Latin]; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meropenem (INN); Meropenem [INN]; Meropenem Hydrate; YOP6PX0BAO; Merrem I.V.; ICI-194660; (4R,5S,6S)-3-(((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4r,5s,6s)-3-{[(3s,5s)-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl}-6-[(1r)-1-Hydroxyethyl]-4-Methyl-7-Oxo-1-Azabicyclo[3.2.0]hept-2-Ene-2-Carboxylic Acid; 96036-03-2 (free); SM 7338; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; ICI 194,660; NCGC00016962-01; ICI 194660; DSSTox_CID_25526; DSSTox_RID_80930; DSSTox_GSID_45526; Meropen; (1R,5S,6S)-2-[(3S,5S)-5-DIMETHYLAMINOCARBONYLPYRROLIDIN-3-YLTHIO]-6-[(R)-1-HYDROXYETHYL]-1-METHYLCARBAPEN-2-EM-3-CARBOXYLIC ACID; (4R,5S,6S)-3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meronem (TN); CAS-96036-03-2; MFCD08600005; Merrem I.V. (TN); SR-01000762894; HSDB 8019; Merrem IV; Meropenem,(S); M2279; BRN 6940582; PubChem17275; Meropenem (closed form); Prestwick0_001106; Prestwick1_001106; Prestwick2_001106; Prestwick3_001106; CHEMBL127; Epitope ID:195064; SCHEMBL34442; BSPBio_001212; (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; MLS001401437; BIDD:GT0851; 4-methyl-7-oxo-1-azabicyclo; SPBio_003086; BPBio1_001334; Meropenem with Sodium Carbonate; DTXSID7045526; GTPL10829; HMS1571M14; HMS2051G08; HMS2090C05; HMS2098M14; HMS3715M14; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, (4R,5S,6S)-; AMY22192; ZINC3808779; 96036-03-2 (anhydr.); Tox21_110715; Tox21_113794; BDBM50129062; AKOS015920140; Tox21_110715_1; CCG-100850; CS-1865; DB00760; KS-5224; NC00100; [3.2.0]hept-2-ene-2-carboxylic acid; NCGC00179259-01; NCGC00179259-06; NCGC00179259-17; NCGC00253670-01; NCGC00262579-02; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid; HY-13678; SMR000469184; AB0012458; AB00514051; D08185; J10087; M05727; S-3680; AB00514051-02; AB00698370-05; pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-; 036M032; Q421670; (4R,5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl); SR-01000762894-3; SR-01000762894-4; Meropenem trihydrate, Antibiotic for Culture Media Use Only; (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-[[(3S,5S)-5-(dimethylaminocarbonyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(S*,5S*),4-alpha,5-beta,6-beta(R*)))-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Bacterial infection [ICD-11: 1A00-1C4Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.9 mL/min/kg
Elimination
70% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 1 hour
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 111.761 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.87%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.3 L/kg
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C17H25N3O5S
PubChem CID
441130
Canonical SMILES
CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O
InChI
1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1
InChIKey
DMJNNHOOLUXYBV-PQTSNVLCSA-N
CAS Number
CAS 96036-03-2
ChEBI ID
CHEBI:43968
TTD Drug ID
D0O5FY
DrugBank ID
DB00760
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Fosfomycin      Streptomyces fradiae     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Pseudomonas aeruginosa PAO1 Microorganism model Pseudomonas aeruginosa
                    Experimental
                    Result(s)		 The combination of fosfomycin plus meropenem is synergistic for pseudomonas aeruginosa PAO1 in a hollow-fiber infection model.
Target and Pathway
Target(s) Bacterial Penicillin binding protein (Bact PBP)  Molecule Info  [3]
References
Reference 1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Reference 2 The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01682-18.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link